Page 79 - 《中国药房》2024年20期
P. 79

左西孟旦治疗感染性休克合并心肌抑制的临床观察
                                                                                         Δ


                            1
                                                     1
                                                                              1
                                                                      1
                                                             1
                                             1
          熊 芳    1, 2* ,刘 超 ,张可祥 ,周岐龙 ,卢 花 ,陈建国 ,岳 希 ,赵建新 ,潘鹏飞 (1. 重庆大学附属三峡
                                                                                      1 #
                                    1
          医院重症医学科,重庆 404100;2.锦州医科大学重庆大学附属三峡医院研究生联合培养基地,重庆 404100)
          中图分类号  R969.4;R542.2      文献标志码  A      文章编号  1001-0408(2024)20-2517-05
          DOI  10.6039/j.issn.1001-0408.2024.20.13
          摘  要  目的  探讨左西孟旦对感染性休克合并心肌抑制患者心脏功能、血流动力学和预后的影响,并评价其安全性。方法  选择
          2021年4月-2023年8月入住重庆大学附属三峡医院重症医学科、经充分液体复苏、平均动脉压(MAP)≥65 mmHg且接受脉搏指
          示连续心输出量(PiCCO)监测的感染性休克合并心肌抑制患者,按随机数字表法分为多巴酚丁胺组和左西孟旦组,每组 20 例。
          两组患者均静脉泵入重酒石酸去甲肾上腺素注射液0.1~2.0 μg/(kg·min)。在此基础上,多巴酚丁胺组患者加用盐酸多巴酚丁胺
          注射液5~10 μg/(kg·min),连续静脉泵入3~7 d;左西孟旦组患者加用左西孟旦注射液0.1~0.2 μg/(kg·min),连续静脉泵入24
          h。比较两组患者治疗前及治疗后24、72 h的心率(HR)和血流动力学指标[收缩压、舒张压、MAP、中心静脉压(CVP)]、PiCCO监
          测指标[心功能指数(CFI)、心指数(CI)、每搏量指数(SVI)、血管外肺水指数、全心舒张末期容积指数、肺血管通透性指数(PVPI)、
          全心射血分数(GEF)、系统血管阻力指数、左心室收缩力指数]和预后指标[用药后3 d内死亡情况、机械通气时间、住重症监护病房
         (ICU)时间、28 d病死率],记录两组患者的不良反应发生情况。结果  与同组治疗前比较,多巴酚丁胺组患者治疗后24 h的CFI、
          CI、GEF和治疗后72 h的CI、GEF以及左西孟旦组患者治疗后24 h的SVI和治疗后72 h的SVI、GEF均显著升高,多巴酚丁胺组患
          者治疗后72 h的PVPI显著降低(P<0.05);与同期多巴酚丁胺组比较,左西孟旦组患者治疗后24 h的HR显著降低,CVP显著升高
         (P<0.05)。给药后3 d内,两组均无患者死亡;其机械通气时间、住ICU时间、28 d病死率和不良反应发生率比较差异均无统计学
          意义(P>0.05)。结论  对于经充分液体复苏、MAP≥65 mmHg且接受PiCCO监测的感染性休克合并心肌抑制患者,左西孟旦在
          改善心脏功能和血流动力学方面的作用与多巴酚丁胺相当,且不会影响患者预后,也不会增加低血压等不良反应的发生风险。
          关键词  左西孟旦;感染性休克;心肌抑制;多巴酚丁胺;脉搏指示连续心输出量监测

          Clinical observation of levosimendan in the treatment of septic shock combined with myocardial depression
                                                      1
          XIONG Fang ,LIU Chao ,ZHANG Kexiang ,ZHOU Qilong ,LU Hua ,CHEN Jianguo ,YUE Xi ,
                                                                                1
                                                                      1
                      1, 2
                                   1
                                                                                                 1
                                                                                                           1
                      1
                                   1
          ZHAO Jianxin ,PAN Pengfei(1. Dept. of Critical Care Medicine, Chongqing University Three Gorges Hospital,
          Chongqing  404100,  China;2.  Jinzhou  Medical  University  Union  Training  Base,  Chongqing  University  Three
          Gorges Hospital, Chongqing 404100, China)
          ABSTRACT   OBJECTIVE To explore the effects of levosimendan on cardiac function, hemodynamics and prognosis of patients
          with  septic  shock  complicated  with  myocardial  depression,  and  evaluate  the  safety  of  levosimendan.  METHODS  Patients  with
          septic shock complicated with myocardial depression who were admitted to the Department of Critical Care Medicine of Chongqing
          University  Three  Gorges  Hospital  from  April  2021  to  August  2023,  underwent  adequate  fluid  resuscitation,  had  a  mean  arterial
          pressure (MAP)  ≥65  mmHg,  and  received  pulse  indicator  continuous  cardiac  output (PiCCO)  monitoring  were  enrolled.  The
          patients  were  randomly  divided  into  dobutamine  group  and  levosimendan  group  according  to  a  random  number  table,  with  20
          patients in each group. Both groups received intravenous infusion of Norepinephrine bitartrate injection at a dose of 0.1-2.0 μg/(kg·min).
          On this basis, the dobutamine group additionally received intravenous infusion of Dobutamine hydrochloride injection at a dose of 5-
          10  μg/(kg·min)  for  3  to  7  days,  while  the  levosimendan  group  additionally  received  intravenous  infusion  of  Levosimendan
          injection  at  a  dose  of  0.1-0.2  μg/(kg·min)  for  24  hours.  Heart  rate (HR)  and  hemodynamic  parameters  [systolic  blood  pressure,
          diastolic  blood  pressure,  MAP,  central  venous  pressure (CVP)],  PiCCO  monitoring  parameters  [cardiac  function  index (CFI),
          cardiac  index (CI),  stroke  volume  index (SVI),  extravascular  lung  water  index,  global  end-diastolic  volume  index,  pulmonary
          vascular  permeability  index (PVPI),  global  ejection  fraction (GEF),  systemic  vascular  resistance  index,  left  ventricular
                                                             contractility  index],  and  prognosis  indicators  [death  within  3
             Δ 基金项目 重庆市自然科学基金面上项目(No.cstc2020jcyj-           days  after  administration,  mechanical  ventilation  time,
          msxmX1069);重庆市科卫联合医学科研项目(No.2020FYYX133);重         intensive  care  unit (ICU)  stay  time,  28-day  mortality  rate]
          庆市卫生健康委中医药科研项目(No.2023WSJK143)                     were compared between the two groups before treatment and at
             *第一作者 主治医师。研究方向:脓毒症的基础与临床研究。
                                                             24  and  72  hours  after  treatment.  Adverse  reactions  were
          E-mail:171511884@qq.com
             # 通信作者 主任医师,硕士生导师,博士。研究方向:脓毒症的基                 recorded  for  both  groups.  RESULTS  Compared  with  before
          础与临床研究。E-mail:ppfswh@126.com                       treatment  in  the  same  group,  CFI,  CI  and  GEF  at  24  hours


          中国药房  2024年第35卷第20期                                              China Pharmacy  2024 Vol. 35  No. 20    · 2517 ·
   74   75   76   77   78   79   80   81   82   83   84